Human dihydroorotate dehydrogenase inhibitors, a novel approach for the treatment of autoimmune and inflammatory diseases

Arzneimittel-Forschung/Drug Research

Volumn 61, Issue 1, 2011, Pages 66-72

  Leban, Johann ^a   Vitt, Daniel ^a  

^a 4SC AG   (Germany)

Author keywords

CAS 75706 12 6; Dihydroorotate dehydrogenase inhibitors; Disease modifying antirheumatic drug; Leflunomide; X ray structure based drug design

Indexed keywords

BREQUINAR; CYCLOSPORIN; DEXAMETHASONE; DIHYDROOROTATE DEHYDROGENASE; DIHYDROOROTATE DEHYDROGENASE INHIBITOR; LEFLUNOMIDE; SC 12267; TERIFLUNOMIDE; UNCLASSIFIED DRUG; URIDINE; VIDOFLUDIMUS;

AUTOIMMUNE DISEASE; CLINICAL TRIAL; CROHN DISEASE; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; INFLAMMATION; MULTIPLE SCLEROSIS; NONHUMAN; REACTION ANALYSIS; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 79952001740     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296169     Document Type: Review

References (50)

1. Woods DD. The relation of p-aminobenzoic acid to the mechanism of the action of sulfanilamide. Br J Exp Path. 1940;21:74.
2. Fildes P. A rational approach to research in chemotherapy. Lancet. 1940;235:955-7.
3. Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff JA. Temporary remissions in acute leukaemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N Engl J Med. 1948;238:787-93.
4. Willkens RF, Watson MA. Methotrexate: a perspective of its use in the treatment of rheumatic diseases. J Lab Clin Med. 1982;100(3):314-21. (Pubitemid 12028701)
5. Steinsson K, Weinstein A, Korn J, Abeles M. Low dose methotrexate in rheumatoid arthritis. J Rheumatol. 1982 Nov-Dec;9(6):860-6. (Pubitemid 13119689)
6. Hitchings GH, Jr. Selective inhibitors of dihydrofolate reductase. Les prix Nobel. 1988;296-313.
7. Elion GB. The purine path of chemotherapy. Science. 1989;24:4900:41-7.
8. Hedstorm L. IMP dehydrogenase: structure, mechanism, and inhibition. Chem Rev. 2009;109(7):2903-28.
9. Hong Z, Craig E. Pleiotropic mechanism of ribavirin antiviral activities. Prog Drug Res. 2002;59:41-69.
10. Fairbanks LD, Bofill M, Ruckemann K, Simmonds HA. Importance of ribunucleotide availability to proliferating T lymphocytes from healthy humans. J Biol Chem., 1995;270(50):29682-9.
11. Löffler M, Jöckel J, Schuster G, Becker C. Dihydroorotatubiquinone oxidoreductase links mitochondria in the biosynthesis of pyrimidine nucleotides. Mol Cell Biochem. 1997;174:125-9. (Pubitemid 27404179)
12. Löffler M, Grein K, Knecht W, Klein A, Bergjohann U. Dihydroorotate Dehydrogenase. Purine Pyrimidine Metab Man. 1998:507-14.
13. Douglas GB. Inhibitors of dihydroorotate dehydrogenase. Exp Opin Ther Pat. 1999;9(1):41-54.
14. Cramer DV. Brequinar sodium. Transplant Proc. 1996;28(2):960-3.
15. Joshi AS, King SY, Zajac BA, Makowka L, Sher LS, Kahan BD, et al. Phase I safety and pharmacokinetic studies of brequinar sodium after single ascending oral doses in stable renal, hepatic, and cardiac allograft recipients. J Clin Pharmacol. 1997;37(12):1121-8. (Pubitemid 28076456)
16. Schiff MH, Strand V, Oed C, Loew-Friedrich I. Leflunomide: efficacy and safety in clinical trials for the treatment of rheumatoid arthritis. Drugs Today 2000;36(6):383-94. (Pubitemid 30451170)
17. Li EK, TamLS, Tomlinson B. Leflunomide in the treatment of rheumatoid arthritis. Clin Ther. 2004;26(4):447-59. (Pubitemid 38586447)
18. Osiri M, Shea B, Robinson V, Suarez-Almazor M, Strand V, Tugwell P, et al. Leflunomide for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2003;(1):CD002047.
19. Prakash A, Jarvis B. Leflunomide: a review of its use in active rheumatic arthritis. Drugs . 1999;58(6):1137-64. (Pubitemid 30055049)
20. Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis. Arthritis Rheum. 2004;50:1939-50.
21. Kiely PD. The broadening use of leflunomide in clinical practice. Hosp Med. 2004;65(12)735-9. (Pubitemid 40090633)
22. Robertson SM, Lang LS. Leflunomide: inhibition of S-antigen induced autoimmuneuveitis in Lewis rats. Agents Action. 1994;42:167-72.
23. O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GPA, Confavraux C, et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology . 2006;66:894-900. (Pubitemid 43739766)
24. Pinto P, Dougados M. Leflunomide in clinical practice. Acta Rheumatol Port. 2006;31(3):215-24.
25. Boyd B, Castaner. Teriflunomide: agent for multiple sclerosis. dihydroorotate dehydrogenase inhibitor. Drugs Future. 2005;30(11):1102-6.
26. Smolen JS, Aletaha D, Keystone E. Superior efficacy of combination therapy for rheumatoid arthris: fact or fiction? Arthritis Rheum. 2005;52:2975-83.
27. Katchamart W, Trudeau J, Phumethum V, Bombardier C. The efficacy and toxicity of Methotrexate (MTX) monotherapy with non-biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis: a systematic review and metaanalysis. Ann RheumDis. 2009;68:1105-12.
28. Bao C, Chen S, Gu Y, Lao Z, Ni L, Yu Q, et al. Leflunomide, a new disease-modifying drug for treating rheumatoid arthritis in methotrexate- controlled phase II clinical trial. Chin Med J. 2003;116(8):1228-34. (Pubitemid 37069873)
29. Weinblatt EM, Dixon J, Falchuk KR. Serious liver disease in a patient receiving metotrexate and leflunomide. Arthritis Rheum 2000;43(11)2609-13.
30. Kirsch BM, Zeyda M, Stuhlmeier K, Grisar J, Smolen JS, Watschinger B, et al. The active metabolite of leflunomide, A77 1726, interferes with dentritic cell function. Arthritis Res Ther. 2005;7(3):R694-703.
31. Siemasko K, Chong ASF, Jäck HM, Gong H, Williams JW, Finnegan A. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J Immunol. 1998 Feb 15;160(4):1581-8. (Pubitemid 28106441)
32. Gonzalez-Alvaro I, Garcia AMO, Dominguez-Jiminez C, et al. Inhibition of TNF and IL-17 production by leflunomide involves the JAK/STAT pathway. Ann Rheum Dis. 2009;68:144-1650.
33. Ullrich A, Knecht W, Fries M, Loffler M. Recombinant expression of N-terminal truncated mutants of the membrane bound mouse, rat and human flavoenzyme dihydroorotate dehydrogenase: a versatile tool to rate inhibitor effects? J Bio Chem. 2001;268(6):1861-8. (Pubitemid 32862722)
34. Liu S, Neidhardt EA, Trudy HG, Ocain T, Clardy J. Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents. Structure. 2000;8(1):25-33. (Pubitemid 30051339)
35. Sutton AE, Clardy, J. The synthesis of potentially selective inhibitors of dihydroorotate dehydrogenase. The utilization of chemoselective Suzuki cross-coupling reactions in a parallel synthesis. Tetrahedron Lett. 2001;42;547.
36. Pospisil P, Kuon T, Scapozza L, Folkers GJ. Methodology and problems of protein-ligand docking: case study of dihydroorotate dehydrogenase, thymidine kinase, and phosphodiesterase 4. J Recept Signal Transduction. 2002;22(1):141-154. (Pubitemid 36169144)
37. Herz T, Wolf K, Kraus J, Kramer B. 4SCan/vADME: intelligent library screening as a shortcut from hits to lead compounds. Exp Opin Drug Metab Toxicol. 2006;2(3):471-83.
38. Wolf K. High-throughput docking, a case study. International workshop on new approaches in drug design and discovery. Schloss Rauischholzhausen, Germany; 2003.
39. Ortez D, Munoz-Colado C, Garcia-Domenech R, Gimeno-Cardona C. Virtual combinatorial syntheses and computational screening of new potentional anti-herpes compounds. J Med Chem. 1999;42:3308-14. (Pubitemid 29409719)
40. Leban J, Saeb W, Garcia G, Baumgartner R, Kramer B. Discovery of a novel series of DHODH inhibitors by a docking procedure and QSAR refinement. Bioorg Med Chem Lett. 2004;14:55-8. (Pubitemid 38010193)
41. Leban J, Kralik M, Mies J, Baumgartner R, Gassen M, Tasler S. Biphenyl-4-ylcarbamoyl thiophene carboxylic acids as potent DHODH inhibitors. Bioorg Med Chem Lett. 2006;15:267-70. (Pubitemid 41680610)
42. Leban J, Kralik M, Mies J, Gassen M, Tentschert K, Baumgartner R. SAR, species specificity, and cellular activity of cyclopentene dicarboxylic acid amides as DHODH inhibitor. Bioorg Med Chem Lett. 2005;4854-7. (Pubitemid 41354821)
43. Baumgartner R, Walloschek M, Kralik M, Gotschlich A, Tasler S, Mies J, et al. Dual binding mode of a novel series of DHODH inhibitors. J Med Chem. 2006;49:1239-47. (Pubitemid 43271880)
44. Walse B, Tamu Tufe V, Svennson B, Fritzson I, Dahlberg L, Khairoullina A, et al. The structure of human dihydroorotate dehydrogenase with and without inhibitor reveal conformational flexibility in the inhibitor and substrate binding sites. Biochemistry. 2008;47:8929-36.
45. Fritzson I, Svensson B, Al-Karadaghi S, Walse B, Wellmar U, Nilsson UJ, et al. Inhibition of human DHODH by 4-hydroxycoumarins, fenamic acids, and N-(alkylcarbonyl)anthranilic acids identified by structure-guided fragment selection. Chem Med Chem. 2010;5:608-17.
46. Castro Palomino Laria JC, Erra Sola M, Lozoya Toribio ME, Navarro Romero E. Amino nicotinic and isonicotinic acid derivates as DHODH inhibitors. WO 2008/077639 (A1): WO 2007EP11401 20071221.
47. Strobl S, Leban J, Baumgartner R, Ammendola A. DHODH Inhibitors - from virtual screening to clinical phase II. Symposium on nucleosides and nucleotides, Stockholm, Sweden; 2009.
48. Press release 4SC AG 28 May, 2009 (www.4sc.com).
49. Fitzpatrick LR, Deml L, Hofman L, Small JS, Groeppel M, Hamm S, et al. A novel immunosuppressive drug (4SC-101) improves TNBS-induced colitis in mice. Inflamm Bowel Dis. 2010;Oct:16(10):1763-77.
50. Kulkarni OP, Sayyyed SG, Kantner C, Ryu M, Schnurr M, Sardy M, et al. 4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr mice. Am J Pathol. 2010;176(6):2840-7.